For research use only. Not for therapeutic Use.
Rohinitib is a potent and specific eIF4A inhibitor. Rohinitib induces cell apoptosis of acute myeloid leukemia (AML) cell lines and reduces the leukemia burden of AML xenograft model. Rohinitib can be used for the research of AML[1].
Rohinitib (6.25-50 nM; 72 h) induces cell apoptosis of AML cell lines and FLT3-ITD-positive AML cell lines[1].
Primary AML cells is more sensitive to Rohinitib (25 nM; 72 h) than normal bone marrow (BM) and FLT3-ITD-positive cells is more sensitive to Rohinitib than FLT3 wild-type AML cells[1].
Rohinitib (0.75 and 1.0 mg/kg; s.c. once daily for 5 consecutive days until mice get moribund) shows anti-AML effects in vivo[1].
| Catalog Number | I042480 |
| CAS Number | 1139253-73-8 |
| Synonyms | (1R,2R,3S,3aR,8bS)-1,8b-dihydroxy-N,6,8-trimethoxy-3a-(4-methoxyphenyl)-N-methyl-3-phenyl-2,3-dihydro-1H-cyclopenta[b][1]benzofuran-2-carboxamide |
| Molecular Formula | C29H31NO8 |
| Purity | ≥95% |
| InChI | InChI=1S/C29H31NO8/c1-30(37-5)27(32)23-24(17-9-7-6-8-10-17)29(18-11-13-19(34-2)14-12-18)28(33,26(23)31)25-21(36-4)15-20(35-3)16-22(25)38-29/h6-16,23-24,26,31,33H,1-5H3/t23-,24-,26-,28+,29+/m1/s1 |
| InChIKey | TZDAVNWDKGYBCW-IDAMAFBJSA-N |
| SMILES | CN(C(=O)C1C(C2(C(C1O)(C3=C(O2)C=C(C=C3OC)OC)O)C4=CC=C(C=C4)OC)C5=CC=CC=C5)OC |
| Reference | [1]. Nishida Y, et alJ. Inhibition of translation initiation factor eIF4a inactivates heat shock factor 1 (HSF1) and exerts anti-leukemia activity in AML. Leukemia. 2021 Sep;35(9):2469-2481. |
